BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ha J, Yan M, Aguilar M, Tana M, Liu B, Frenette CT, Bhuket T, Wong RJ. Race/Ethnicity-specific Disparities in Hepatocellular Carcinoma Stage at Diagnosis and its Impact on Receipt of Curative Therapies. J Clin Gastroenterol. 2016;50:423-430. [PMID: 26583267 DOI: 10.1097/mcg.0000000000000448] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Li J, Hansen BE, Peppelenbosch MP, De Man RA, Pan Q, Sprengers D. Factors associated with ethnical disparity in overall survival for patients with hepatocellular carcinoma. Oncotarget 2017;8:15193-204. [PMID: 28122352 DOI: 10.18632/oncotarget.14771] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
2 Dewdney B, Roberts A, Qiao L, George J, Hebbard L. A Sweet Connection? Fructose's Role in Hepatocellular Carcinoma. Biomolecules 2020;10:E496. [PMID: 32218179 DOI: 10.3390/biom10040496] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
3 Paro A, Dalmacy D, Tslimigras DI, Cloyd J, Ejaz A, Pawlik TM. Association of County-Level Upward Economic Mobility with Stage at Diagnosis and Receipt of Curative-Intent Treatment among Patients with Hepatocellular Carcinoma. Ann Surg Oncol 2022. [PMID: 35441305 DOI: 10.1245/s10434-022-11726-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Dakhoul L, Gawrieh S, Jones KR, Ghabril M, McShane C, Orman E, Vilar-Gomez E, Chalasani N, Nephew L. Racial Disparities in Liver Transplantation for Hepatocellular Carcinoma Are Not Explained by Differences in Comorbidities, Liver Disease Severity, or Tumor Burden. Hepatol Commun 2019;3:52-62. [PMID: 30619994 DOI: 10.1002/hep4.1277] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
5 Shaltiel T, Zheng S, Siderides C, Gleeson EM, Carr J, Pletcher ER, Cohen NA, Golas BJ, Magge DR, Labow DM, Branch AD, Sarpel U. Hepatitis C-positive Black patients develop hepatocellular carcinoma at earlier stages of liver disease and present with a more aggressive phenotype. Cancer 2021;127:1395-406. [PMID: 33629759 DOI: 10.1002/cncr.33377] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Frenette CT. Increasing Awareness on Racial Disparities in Liver Transplantation for Hepatocellular Carcinoma in the United States. Hepatol Commun 2019;3:5-7. [PMID: 30619989 DOI: 10.1002/hep4.1299] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Sempokuya T, Wien EA, Pattison RJ, Ma J, Wong LL. Factors associated with 5-year survival of combined hepatocellular and cholangiocarcinoma. World J Hepatol 2020; 12(11): 1020-1030 [PMID: 33312426 DOI: 10.4254/wjh.v12.i11.1020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Robinson A, Ohri A, Liu B, Bhuket T, Wong RJ. One in five hepatocellular carcinoma patients in the United States are Hispanic while less than 40% were eligible for liver transplantation. World J Hepatol 2018; 10(12): 956-965 [PMID: 30631400 DOI: 10.4254/wjh.v10.i12.956] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
9 Scaglione S, Adams W, Caines A, Devlin P, Mittal S, Singal AG, Parikh ND. Association Between Race/Ethnicity and Insurance Status with Outcomes in Patients with Hepatocellular Carcinoma. Dig Dis Sci. 2020;65:1669-1678. [PMID: 31643036 DOI: 10.1007/s10620-019-05890-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
10 Gutin L, Yao F, Dodge JL, Grab J, Mehta N. Comparison of Liver Transplant Wait-List Outcomes Among Patients With Hepatocellular Carcinoma With Public vs Private Medical Insurance. JAMA Netw Open 2019;2:e1910326. [PMID: 31469395 DOI: 10.1001/jamanetworkopen.2019.10326] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
11 Goyes D, Nsubuga JP, Medina-Morales E, Barba R, Patwardhan V, Saberi B, Fricker Z, Bonder A. Race/Ethnicity Is Not Independently Associated with Risk of Adverse Waitlist Removal among Patients with HCC Exception Points. J Clin Med 2021;10:5826. [PMID: 34945122 DOI: 10.3390/jcm10245826] [Reference Citation Analysis]
12 Thylur RP, Roy SK, Shrivastava A, LaVeist TA, Shankar S, Srivastava RK. Assessment of risk factors, and racial and ethnic differences in hepatocellular carcinoma. JGH Open 2020;4:351-9. [PMID: 32514436 DOI: 10.1002/jgh3.12336] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
13 Singal AG, Tiro JA, Marrero JA, McCallister K, Mejias C, Adamson B, Bishop WP, Santini NO, Halm EA. Mailed Outreach Program Increases Ultrasound Screening of Patients With Cirrhosis for Hepatocellular Carcinoma. Gastroenterology. 2017;152:608-615.e4. [PMID: 27825963 DOI: 10.1053/j.gastro.2016.10.042] [Cited by in Crossref: 48] [Cited by in F6Publishing: 52] [Article Influence: 8.0] [Reference Citation Analysis]
14 Tejedor M, Selzner N, Berenguer M. Are MELD and MELDNa Still Reliable Tools to Predict Mortality on the Liver Transplant Waiting List? Transplantation 2022. [PMID: 35594480 DOI: 10.1097/TP.0000000000004163] [Reference Citation Analysis]
15 Pomenti S, Gandle C, Abu Sbeih H, Phipps M, Livanos A, Guo A, Yeh J, Burney H, Liu H, Dakhoul L, Kettler C, Gawrieh S, deLemos A, Scanga A, Chalasani N, Miller E, Wattacheril J. Hepatocellular Carcinoma in Hispanic Patients: Trends and Outcomes in a Large United States Cohort. Hepatol Commun 2020;4:1708-16. [PMID: 33163839 DOI: 10.1002/hep4.1575] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Ajayi F, Jan J, Singal AG, Rich NE. Racial and Sex Disparities in Hepatocellular Carcinoma in the USA. Curr Hepatol Rep 2020;19:462-9. [PMID: 33828937 DOI: 10.1007/s11901-020-00554-6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Wang Z, Gu X, Thrift AP. Factors associated with favorable survival outcomes for Asians with hepatocellular carcinoma: A sequential matching cohort study. PLoS One 2019;14:e0214721. [PMID: 30943273 DOI: 10.1371/journal.pone.0214721] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
18 Jaruvongvanich V, Assavapongpaiboon B, Wong L. Racial/ethnic disparities in gallbladder cancer receipt of treatments. J Gastrointest Oncol 2018;9:348-53. [PMID: 29755774 DOI: 10.21037/jgo.2017.11.09] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
19 Stewart SL, Kwong SL, Bowlus CL, Nguyen TT, Maxwell AE, Bastani R, Chak EW, Chen Jr MS. Racial/ethnic disparities in hepatocellular carcinoma treatment and survival in California, 1988-2012. World J Gastroenterol 2016; 22(38): 8584-8595 [PMID: 27784971 DOI: 10.3748/wjg.v22.i38.8584] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 32] [Article Influence: 6.5] [Reference Citation Analysis]
20 Singal AG, Tiro JA, Murphy CC, Marrero JA, McCallister K, Fullington H, Mejias C, Waljee AK, Pechero Bishop W, Santini NO, Halm EA. Mailed Outreach Invitations Significantly Improve HCC Surveillance Rates in Patients With Cirrhosis: A Randomized Clinical Trial. Hepatology 2019;69:121-30. [PMID: 30070379 DOI: 10.1002/hep.30129] [Cited by in Crossref: 17] [Cited by in F6Publishing: 27] [Article Influence: 5.7] [Reference Citation Analysis]
21 Malespin M, May EJ, Nephew LD, Paul S, McCary A, Kilaru S, Mukhtar NA, Hassan MA, Brady CW. AASLD Deepens Commitment to Diversity, Equity, and Inclusion. Hepatology 2021;74:2216-25. [PMID: 34028073 DOI: 10.1002/hep.31918] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Samant H, Kohli K, Patel K, Shi R, Jordan P, Morris J, Schwartz A, Alexander JS. Clinical Presentation of Hepatocellular Carcinoma in African Americans vs. Caucasians: A Retrospective Analysis. Pathophysiology 2021;28:387-99. [PMID: 35366282 DOI: 10.3390/pathophysiology28030026] [Reference Citation Analysis]
23 Robinson A, Tavakoli H, Liu B, Bhuket T, Wong RJ. Advanced Hepatocellular Carcinoma Tumor Stage at Diagnosis in the 1945-1965 Birth Cohort Reflects Poor Use of Hepatocellular Carcinoma Screening. Hepatol Commun 2018;2:1147-55. [PMID: 30202827 DOI: 10.1002/hep4.1236] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
24 Corey KE, Gawrieh S, deLemos AS, Zheng H, Scanga AE, Haglund JW, Sanchez J, Danford CJ, Comerford M, Bossi K, Munir S, Chalasani N, Wattacheril J. Risk factors for hepatocellular carcinoma in cirrhosis due to nonalcoholic fatty liver disease: A multicenter, case-control study. World J Hepatol 2017; 9(7): 385-390 [PMID: 28321274 DOI: 10.4254/wjh.v9.i7.385] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
25 Lee RM, Gamboa AC, Turgeon MK, Yopp A, Ryon EL, Kronenfeld JP, Goel N, Wang A, Lee AY, Luu S, Hsu C, Silberfein E, Maithel SK, Russell MC. Dissecting disease, race, ethnicity, and socioeconomic factors for hepatocellular carcinoma: An analysis from the United States Safety Net Collaborative. Surg Oncol 2020;35:120-5. [PMID: 32871546 DOI: 10.1016/j.suronc.2020.08.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Khamis ZI, Pang X, Cui Z, Sang QA, Zhang J. Cytochrome P450-2D6: A novel biomarker in liver cancer health disparity. PLoS One 2021;16:e0257072. [PMID: 34597305 DOI: 10.1371/journal.pone.0257072] [Reference Citation Analysis]
27 Aly A, Ronnebaum S, Patel D, Doleh Y, Benavente F. Epidemiologic, humanistic and economic burden of hepatocellular carcinoma in the USA: a systematic literature review. Hepat Oncol 2020;7:HEP27. [PMID: 32774837 DOI: 10.2217/hep-2020-0024] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
28 Rosenblatt R, Wahid N, Halazun KJ, Kaplan A, Jesudian A, Lucero C, Lee J, Dove L, Fox A, Verna E, Samstein B, Fortune BE, Brown RS Jr. Black Patients Have Unequal Access to Listing for Liver Transplantation in the United States. Hepatology 2021;74:1523-32. [PMID: 33779992 DOI: 10.1002/hep.31837] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
29 Zhou K, Pickering TA, Gainey CS, Cockburn M, Stern MC, Liu L, Unger JB, El-Khoueiry AB, Terrault NA. Presentation, Management, and Outcomes Across the Rural-Urban Continuum for Hepatocellular Carcinoma. JNCI Cancer Spectr 2021;5:pkaa100. [PMID: 33442663 DOI: 10.1093/jncics/pkaa100] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]